Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple.Please ensure you read all information detailed under a drug.
Royal Berkshire NHS Foundation Trust >> Formulary Item injection
Idarubicin Hydrochloride (Zavedos®)
Formulary
Royal Berkshire NHS Foundation Trust >> Formulary Item capsules / injection
Mitomycin
Formulary
Royal Berkshire NHS Foundation Trust >> Formulary Item injection
Mitoxantrone (Mitozantrone)
Formulary
Royal Berkshire NHS Foundation Trust >> Formulary Item infusion
Pegylated Liposomal Doxorubicin Hydrochloride
Formulary
NHS England Commissioning requirements for funding apply; approval may be required prior to use. Please contact pharmacy for details prior to prescribing this item.
Royal Berkshire NHS Foundation Trust >> Formulary Item infusion ONLY in line with NICE TA - link below
NHS England Commissioning requirements for funding apply; approval may be required prior to use. Please contact pharmacy for details prior to prescribing this item.
Royal Berkshire NHS Foundation Trust >> Formulary Item infusion ONLY in line with NICE TA - link below
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item see generic drug for details (brand may not be available - contact pharmacy for advise)
Doxorubicin Hydrochloride (Zavedos®)
Non Formulary
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item see generic drug for details (brand may not be available - contact pharmacy for advise)
Mitoxantrone (Onkotrone®)
Non Formulary
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item see generic drug for details (brand may not be available - contact pharmacy for advise)
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Medicines that should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the primary care provider that the prescribing responsibility has been transferred. Where applicable, shared care protocols will be agreed and must be adhered to. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s)(DTC) and approved by Berkshire West APC.
Drugs that have been reviewed and not recommended for prescribing. These drugs are not considered a cost-effective use of scarce NHS resources. There may be individual patient-specific or clinical reasons why a drug deemed low priority may be suitable for a particular patient. This is for the GP to consider, weighing up the reasons against his/her allocated CCG budget. Where the decision is made to prescribe a low priority drug, detailed documentation must be included in the patients' notes for audit purposes. *Please note that low priority drug requests are unsuitable for the Case Review Committee and therefore should not be sent to this committee.
Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with the BNF or other recognised national formulary. Primary care prescribers take full responsibility for prescribing
Medicines which should be prescribed by specialists only
ONLY in line with NICE TA - link below 
